• Publications
  • Influence
Tumor-associated macrophages in breast cancer: Innocent bystander or important player?
TLDR
The functional aspects of TAMs and the rationale and current evidence for TAMs as a therapeutic target in breast cancer are summarized and macrophage-targeted treatment strategies are developed and are currently being evaluated in clinical breast cancer trials. Expand
Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck
TLDR
It is shown that hypoxia induces activation of AKT both in vitro and in vivo, and that hypoxic cells can be specifically targeted by pAKT-inhibition, a potential way to overcome therapy resistance induced by Hypoxia and improve patient outcome. Expand
Biodistribution and PET Imaging of Labeled Bispecific T Cell–Engaging Antibody Targeting EpCAM
TLDR
The authors' data support using 89Zr and IRDye 800CW to evaluate tumor and tissue uptake kinetics of bispecific T cell engager antibody constructs in preclinical and clinical settings provides real-time information about AMG 110 distribution and tumor uptake in vivo. Expand
Molecular Imaging in Cancer Drug Development
TLDR
This review focuses on current applications of molecular imaging in the development of small molecules, antibodies, and antihormonal anticancer drugs. Expand
89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake
TLDR
This first-in-human study shows high, specific 89Zr-AMG 211 accumulation in CD3-rich lymphoid tissues, as well as a clear, inter- and intraindividual heterogeneous tumor uptake. Expand
Molecular Imaging of Radiolabeled Bispecific T-Cell Engager 89Zr-AMG211 Targeting CEA-Positive Tumors
TLDR
89Zr-AMG211 showed dose-dependent CEA-specific tumor targeting and localization in viable tumor tissue and was manufactured according to Good Manufacturing Practice (GMP) guidelines for clinical trial NCT02760199. Expand
Abstract A85: Preclinical evaluation of the radiolabeled bispecific T-cell engager 89Zr-AMG 211 targeting CEA-positive tumors
TLDR
This study showed dose-dependent CEA-specific targeting of 89Zr-AMG 211 in LS174T bearing mice with the highest uptake 3 h after injection and a prolonged imageable tumor retention up to 48 h, and showed similar CEA binding as unlabeled AMG 211. Expand
Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate
TLDR
The biodistribution and tumor targeting of zirconium-89 (89Zr) labeled ERY974 in mouse models using immuno-positron emission tomography (PET) imaging and ex vivo autoradiography demonstrated a preferential distribution of [89ZR]Zr-N-suc-Df-ERY974 to T cell rich tumor tissue. Expand
...
1
2
...